Status:
UNKNOWN
Exercise Targeting Cognitive Impairment in Parkinson's Disease
Lead Sponsor:
University of Southern California
Collaborating Sponsors:
National Parkinson Foundation
University of California, Los Angeles
Conditions:
Parkinson's Disease
Eligibility:
All Genders
30-85 years
Phase:
NA
Brief Summary
The aim of this application is to compare and elucidate the effects of skill-based versus aerobic exercise versus control on mild cognitive impairment (MCI) of the executive function (EF) subtype in P...
Detailed Description
Mild cognitive impairment (MCI), particularly of the executive function (EF) subtype, is common in Parkinson's disease (PD) and transitions to dementia, increased fall risk, and poor quality of life. ...
Eligibility Criteria
Inclusion
- willing and able to provide informed consent
- confirmed diagnosis of idiopathic PD based on the United Kingdom Brain Bank criteria
- Mild cognitive impairment (Level II criteria Movement Disorder Task Force)
- medically eligible for MRI imaging
- able to provide a written medical clearance from their primary physician to participate in exercise
- stable PD medications for 3 months
Exclusion
- a Hoehn \& Yahr staging greater than 2.5 at screening
- severe cardiac disease (New York Heart Association classification IIIV)
- history of an abnormal stress test
- clinically significant medical or psychiatric illness
- electrically, magnetically, or mechanically activated implant (such as cardiac pacemakers or intracerebral vascular clip)
- metal in any part of the body including metal injury to the eye
- past history of brain lesions (such as stroke)
- seizures or unexplained spells of loss of consciousness
- family history of epilepsy
- physical therapy within 6 months of the study
- symptomatic orthostatic hypotension at the screening visit
- orthopedic and other movement-influencing diseases such as arthritis or total hip joint replacement
- requirement for central nervous system active therapies (e.g. hypnotics, antidepressants, anxiolytics)
- moderate or severe depression or apathy using the Geriatric depression scale and Apathy scale
- taking anticholinesterase inhibitors
- taking anticholinergic medication
- PD dementia
- Colorblindness
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT02267785
Start Date
October 1 2014
End Date
December 1 2019
Last Update
May 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Southern California
Los Angeles, California, United States, 90033-4606